The COVID-19 pandemic has increased SARS-CoV-2 research globally resulting in three publicly available vaccines from Moderna, Pfizer (mRNA-based), and Johnson & Johnson (viral vector-based).
Between preventative vaccines and palliative treatment for the sickest COVID-19 patients lies the realm of existing drugs that could be repurposed for antiviral prophylaxis.
Fast track vaccine development process by conducting assays in 96- or 384-well plates based on enumeration of foci, plaque or single infected cells.
